亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

湖北武漢遠成共創科技有限公司銷售部  

肉桂酸、肉桂醛、肉桂醇、桂酸甲酯、桂酸乙酯、茶堿、氯霉素、氨甲環酸(傳明酸)、硝酸咪康唑、醋酸氯己定、鹽酸苯乙雙胍、氫氯噻嗪、右旋糖酐20(40、70)、丙酸氯倍他索、樟腦磺酸鈉

搜索
新聞中心
產品分類
聯系方式
  • 聯系人:張澤
  • 電話:027-68886696
  • 郵件:ycyy03@yccreate.com
  • 傳真:027-68886696-956
  • QQ:2355327131
站內搜索
 
榮譽資質
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 供應現貨地瑞那韋
供應現貨地瑞那韋
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
型號 206361-99-1
規格 99%
過期 長期有效
更新 2013-11-08 08:56
 
詳細信息


地瑞那韋
CAS 號:206361-99-1
英文名稱:Darunavir
英文化學名:[(3R,3aS,6aR)-2,3,3a,4,5,6a-Hexahydrofuro[5,4-b]furan-3-yl]-N-[(2S,3R)-4-[(4-aminophenyl) sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
分子式:C27H37N3O7S
分子量:547.66          含 量:98.5%
熔 點:74-76℃        外 觀:白色非結晶固體
用 途:第二代艾滋病病毒1號蛋白酶抑制劑;結構上類似安普那韋。地瑞那韋是新型非肽類蛋白酶抑制劑,臨床上地瑞那韋與利托那韋合用,用于治療曾經接受治療的人免疫缺陷病毒(HIV)感染患者,本品對其他抗HIV治療無效的患者具有較好的療效及耐受性。
     

©2025 湖北武漢遠成共創科技有限公司銷售部 版權所有   技術支持:化工網   訪問量:19987  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |